Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
December 17, 2024 06:30 ET
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033 - Projected to Generate Revenues of $20.63 Billion by 2028, Fueled by Advances in Liquid Biopsy and Personalized Medicine
December 13, 2024 09:49 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033" report has been added to ResearchAndMarkets.com's offering.The cell free DNA (cfDNA)...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
December 10, 2024 08:30 ET
|
Silexion Therapeutics Corp
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Nano Drug Delivery System (NDDS) in Cancer Therapy Global Industry Research Report 2024 - Global Forecast to 2030 with Competitive Profiles of 45+ Key Players
December 03, 2024 10:04 ET
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "NDDS in Cancer Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for NDDS in...
Exosome Diagnostics & Therapeutics Market Assessment 2025-2030 Featuring Strategic Profiles of the Industry's Leading and Emerging Players
November 28, 2024 06:56 ET
|
Research and Markets
Dublin, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The "Exosome Diagnostics & Therapeutics Market by Product, Application, End User - Global Forecast 2025-2030" report has been added to ...
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
November 22, 2024 16:30 ET
|
Silexion Therapeutics Corp
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Patient Derived Xenograft (PDX) Models Market Expects Significant Growth, Reaching $710 Million by 2028 - Global Long-term Forecasts to 2033
November 21, 2024 11:30 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Patient Derived Xenograft (PDX) Models Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The patient derived...
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
November 20, 2024 08:30 ET
|
Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...
Precision Medicine Software Market Report 2024-2029: Industry Trends, Business Opportunities, Competitive Intelligence, Regional Growth Forecasts
October 31, 2024 07:43 ET
|
Research and Markets
Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "Precision Medicine Software Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Precision Medicine...
Modifi Biosciences Acquired by Merck
October 23, 2024 07:05 ET
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...